Q-omics provides the consensus-scored MTX3 profile across patient tissues and cancer cell-line models. MTX3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MTX3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MTX3 RNA expression shows 20,226 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, HNSC, and UVM as cancer lineages where MTX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTX3 survival associations across molecular data types. MTX3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTX3 RNA expression–survival associations across cancer types. High MTX3 expression shows unfavorable associations in OV, STAD, KIRP, LGG and UVM, but favorable associations in HNSC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for MTX3 RNA expression.
This table summarizes MTX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTX3 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, LUSC and READ. The HNSC box plot shows higher MTX3 RNA expression in tumor versus normal tissue (log2 FC = +0.915, t-test p < 0.001).
This table shows molecular features associated with MTX3 in patient tissues and cancer cell lines. In patient samples, MTX3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
